The latest price target for Soleno Therapeutics (NASDAQ:SLNO) was reported by HC Wainwright & Co. on September 3, 2024. The analyst firm set a price target for $70.00 expecting SLNO to rise to within 12 months (a possible 32.75% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Soleno Therapeutics (NASDAQ:SLNO) was provided by HC Wainwright & Co., and Soleno Therapeutics initiated their buy rating.

There is no last upgrade for Soleno Therapeutics

There is no last downgrade for Soleno Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Soleno Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Soleno Therapeutics was filed on September 3, 2024 so you should expect the next rating to be made available sometime around September 3, 2025.

While ratings are subjective and will change, the latest Soleno Therapeutics (SLNO) rating was a initiated with a price target of $0.00 to $70.00. The current price Soleno Therapeutics (SLNO) is trading at is $52.73, which is within the analyst’s predicted range.